PO23-786 ASSOCIATION BETWEEN BASELINE LDL-C, TRIGLYCERIDES, AND HDL-C LEVELS AND THE LIPID-ALTERING AND HS-CRP EFFICACIES OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: THE VYTAL STUDY
Publication
, Conference
Goldberg, RB; Guyton, JR; Mazzone, T; Weinstock, RS; Polis, A; Tomassini, JE; Tershakovec, AM
Published in: Atherosclerosis Supplements
June 2007
Duke Scholars
Published In
Atherosclerosis Supplements
DOI
ISSN
1567-5688
Publication Date
June 2007
Volume
8
Issue
1
Start / End Page
209 / 209
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Goldberg, R. B., Guyton, J. R., Mazzone, T., Weinstock, R. S., Polis, A., Tomassini, J. E., & Tershakovec, A. M. (2007). PO23-786 ASSOCIATION BETWEEN BASELINE LDL-C, TRIGLYCERIDES, AND HDL-C LEVELS AND THE LIPID-ALTERING AND HS-CRP EFFICACIES OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: THE VYTAL STUDY. In Atherosclerosis Supplements (Vol. 8, pp. 209–209). Elsevier BV. https://doi.org/10.1016/s1567-5688(07)71796-8
Goldberg, R. B., J. R. Guyton, T. Mazzone, R. S. Weinstock, A. Polis, J. E. Tomassini, and A. M. Tershakovec. “PO23-786 ASSOCIATION BETWEEN BASELINE LDL-C, TRIGLYCERIDES, AND HDL-C LEVELS AND THE LIPID-ALTERING AND HS-CRP EFFICACIES OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: THE VYTAL STUDY.” In Atherosclerosis Supplements, 8:209–209. Elsevier BV, 2007. https://doi.org/10.1016/s1567-5688(07)71796-8.
Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Tomassini JE, et al. PO23-786 ASSOCIATION BETWEEN BASELINE LDL-C, TRIGLYCERIDES, AND HDL-C LEVELS AND THE LIPID-ALTERING AND HS-CRP EFFICACIES OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: THE VYTAL STUDY. In: Atherosclerosis Supplements. Elsevier BV; 2007. p. 209–209.
Goldberg, R. B., et al. “PO23-786 ASSOCIATION BETWEEN BASELINE LDL-C, TRIGLYCERIDES, AND HDL-C LEVELS AND THE LIPID-ALTERING AND HS-CRP EFFICACIES OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: THE VYTAL STUDY.” Atherosclerosis Supplements, vol. 8, no. 1, Elsevier BV, 2007, pp. 209–209. Crossref, doi:10.1016/s1567-5688(07)71796-8.
Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Tomassini JE, Tershakovec AM. PO23-786 ASSOCIATION BETWEEN BASELINE LDL-C, TRIGLYCERIDES, AND HDL-C LEVELS AND THE LIPID-ALTERING AND HS-CRP EFFICACIES OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: THE VYTAL STUDY. Atherosclerosis Supplements. Elsevier BV; 2007. p. 209–209.
Published In
Atherosclerosis Supplements
DOI
ISSN
1567-5688
Publication Date
June 2007
Volume
8
Issue
1
Start / End Page
209 / 209
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology